WO2023089377 - PD-1 ANTIBODIES AND USES THEREOF
National phase entry:
Publication Number
WO/2023/089377
Publication Date
25.05.2023
International Application No.
PCT/IB2022/000705
International Filing Date
17.11.2022
Title **
[English]
PD-1 ANTIBODIES AND USES THEREOF
[French]
ANTICORPS PD-1 MODIFIÉS ET LEURS UTILISATIONS
Applicants **
MIROBIO LIMITED
First Floor, Winchester House
Heatley Road, Oxford Science Park
Oxford OX4 4GE, GB
Inventors
PALUCH, Christopher
First Floor, Winchester House
Heatley Road, Oxford Science Park
Oxford OX4 4GE, GB
MURRAY, Lynne
First Floor, Winchester House
Heatley Road, Oxford Sceince Park
Oxford OX4 4GE, GB
Priority Data
63/281,404
19.11.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 4911 | |
| EPO | Filing, Examination | 84740 | |
| Japan | Filing | 591 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 31960 |
Total: 122777 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
In some aspects, provided herein are antibodies that bind to PD-1. Antibodies provided herein, in some cases, agonize PD-1 signaling. Antibodies provided herein, in some cases, have modified Fc region. In other aspects, provided herein are compositions, methods of use, methods of making, and kits relating to antibodies that bind to PD-1.[French]
Dans certains aspects, la présente invention concerne des anticorps qui se lient à PD-1. Les anticorps selon l'invention, dans certains cas, ont un effet agoniste de la signalisation PD-1. Les anticorps selon l'invention, dans certains cas, ont une région Fc modifiée. Dans d'autres aspects, l'invention concerne des compositions, des méthodes d'utilisation, des procédés de fabrication et des kits associés à des anticorps qui se lient à PD-1.